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Superoxide productionThe respiratory chain bc1 complex is central to mitochondrial bioenergetics and the target of antiprotozoals. We
characterized a modiﬁed yeast bc1 complex that more closely resemble Plasmodium falciparum enzyme. The
mutant version was generated by replacing ten cytochrome b Qo site residues by P. falciparum equivalents. The
Plasmodium-like changes caused a major dysfunction of the catalytic mechanism of the bc1 complex resulting
in superoxide overproduction and respiratory growth defect. The defect was corrected by substitution of the
conserved residue Y279 by a phenylalanine, or by mutations in or in the vicinity of the hinge domain of the
iron–sulphur protein. It thus appears that side-reactions can be prevented by the substitution Y279F or the
modiﬁcation of the iron–sulphur protein hinge region. Interestingly, P. falciparum— and all the apicomplexan—
contains anunusual hinge region.We replaced the yeast hinge region by the Plasmodium version and combined it
with the Plasmodium-like version of the Qo site. This combination restored the respiratory growth competence. It
could be suggested that, in the apicomplexan, the hinge region and the cytochrome b Qo site have co-evolved to
maintain catalytic efﬁciency of the bc1 complex Qo site.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Themitochondrial respiratory chain complex III or bc1 complex is cen-
tral to mitochondrial bioenergetics and the target of antiprotozoals, such
as atovaquone, and fungicide drugs used to control human and plant
pathogens. It is a multimeric enzyme. Three subunits form the catalytic
core contain the redox-active groups haems and FeS, namely two cyto-
chromes b and c1 and the iron-sulphur protein (ISP). The structures of
several complexes have been solved. They share the same catalytic core.
The central and largest subunit is cytochrome b, a predominantly hydro-
phobic protein consisting of eight transmembrane helices. Cytochrome bone reduction site; Cyt b/c,
e; SOD, superoxide dismutase;
tivity reported on bc1 complex
tain 50% inhibition
ory, Michigan State University,
e Biology of theCell (I2BC), CEA,
8 Gif-sur-Yvette, France.
ier@cgm.cnrs-gif.fr
ark, University of Nottingham,is mitochondrially encoded in all eukaryotes while the other subunits are
nuclearly encoded.
The bc1 complex catalyses the transfer of electrons fromubiquinol to
cytochrome c and couples this electron transfer to the vectorial translo-
cation of protons across the inner mitochondrial membrane, contribut-
ing to the proton motive force used for ATP synthesis by the ATP
synthase. The catalytic mechanism, called the Q-cycle (see for instance
[1,2]), bifurcates electron ﬂow across high- and low-potential electron
transfer chains within the bc1 complex, and requires two distinct
quinone-binding sites (Qo, quinol oxidation site, and Qi, quinone reduc-
tion site), which are located on opposite sides of the membrane and
linked by a transmembrane electron-transfer pathway, reducing one
molecule of ubiquinone per two molecules of ubiquinol oxidised. Cyto-
chrome b provides both the Qo and Qi pockets and the (low potential)
transmembrane electron pathway (via haems bL and bH). The high
potential chain from Qo to cytochrome c is formed by the ISP and cyto-
chrome c1. An unusual property of the catalytic cycle of the bc1 complex
is the role of the C-terminal, extrinsic domain of the ISP (the [2Fe–2S]-
containing ‘headgroup’) which acts as a tethered, mobile substrate,
shuttling electrons from Qo-bound ubiquinol within cytochrome b
to the haem of cytochrome c1, alternately docking with these protein
partners [3].
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to form one mechanism to assist in preventing energetically wasteful
electron transferring bypass reactions, such as double reduction of the
high potential chain [4]. Movement of the ISP headgroup is thought to
be facilitated by relaxation of a short 310 helical and turn region of the
structure known as the ‘hinge’ or ‘linker’, which connects the C-terminal
domain of the ISP to its helical transmembrane anchor [5–7].
The Qo site is a relatively large domain formed from components
encompassing amino acid residues 120–150 and 260–300 of the cyto-
chrome b. On the basis of structural and mutational analysis, Qo inhibi-
tors can be separated into two classes by their mode of binding ([8,9]).
For instance, azoxystrobin binds in the so-called ‘haem bL proximal’ do-
main of the Qo site whereas stigmatellin and atovaquone bind in the
‘haem bL distal’domain, occupying the region of theQo site close to the in-
terfacewith the ISP. Several atomic structures of the yeast (Saccharomyces
cerevisiae) bc1 complexwith boundQo site inhibitors are available. Of par-
ticular interest is the structure of the yeast complexwith the anti-malarial
drug atovaquone bound [10].
To date, atovaquone (in combination with proguanil) is the sole bc1
complex inhibitor used as antimalarial drug in treatment and causal
prophylaxis. The compound is also active against Pneumocystis jirovecii,
Toxoplasma gondii, Babesia sp. and other pathogens. Unfortunately,
atovaquone-resistant parasite populations can rapidly emerge during
therapy, leading to treatment failure (see for instance [11–13]). In the
humanmalaria parasite Plasmodium falciparum, the resistance is caused
by themutation of cytochrome b residue Y268 (Y279 yeast numbering)
in the drug target. New drugs are needed and different compounds are
currently being studied (see for instance [14–16]). While the necessary
gold standard, enzymological and physicochemical investigations of the
parasite enzyme required for the development and study of new drugs
are technically challenging due to the difﬁculties in preparing mito-
chondrial fractions from this organism. Easy-to-use models that mimic
the parasite enzyme facilitate the analysis of new drugs and the study
of the development of resistancemutations. Yeast provides a useful sur-
rogate model as cytochrome b amino acid sequences, in particular at Qo
and Qi sites, are highly conserved between organisms. In addition, yeast
is amenable to mitochondrial transformation and site-directed modiﬁ-
cation of mtDNA genes. The yeast Qo and Qi sites can thus be recon-
structed to mimic the parasite active domains. In a previous study, we
generated a series of yeast mutants by replacing yeast Qo site residues
by P. falciparum or human residues to explore the variations in the Qo
site that could explain the differential sensitivity to atovaquone be-
tween these species [17]. Here we investigated the effect of inter-
species variations on the catalytic activity of the enzyme.
We characterized amodiﬁed yeast bc1 complex thatmore closely re-
sembles that of the human malaria parasite P. falciparum. The mutant
version was generated by replacing ten cytochrome b Qo site residues
by P. falciparum equivalents.Wemeasured the effect of multiple chang-
es on the respiratory growth competence, on the bc1 complex activity
and its sensitivity to inhibitors and on superoxide production. The Plas-
modium-like changes caused a severe dysfunction of the complex
resulting in increased superoxide production. We then investigated
ways to restore the respiratory competence.2. Materials and methods
2.1. Materials and growth media
Equine cytochrome c, decylubiquinone, azoxystrobin, antimycin,
atovaquone, superoxide dismutase, and catalase were obtained from
Sigma Aldrich. The following media were used for the growth of
yeast: YPD (1% yeast extract, 2% peptone and 3% glucose), YPGal
(1% yeast extract, 2% peptone and 2% galactose), YPeth (1% yeast
extract, 2% peptone and 3% ethanol) and YPG (1% yeast extract, 2%
peptone and 2% glycerol).2.2. Yeast strains and plasmids
The multiple mutations were introduced in yeast cytochrome b by
side-directed mutagenesis and mitochondrial transformation [17,18].
In all experiments, control and mutants have identical nuclear and mi-
tochondrial genomes with the exception of the mutations introduced
in the cytochrome b gene. Three series of strains were used in this
work. Diploids were used for the mitochondrial preparation and bio-
chemical analysis. Suppressors were issued from the haploid strains
withW303-1B nuclear background. Strainswithmodiﬁed ISPwere con-
structed from haploid strains harbouring a deletion of the nuclear RIP1
gene, encoding the ISP, and derived from JPJ1 [19]. The strains are listed
in Table S1. The centromeric plasmid carrying wild-type (wt) RIP1
under the control of its own promoter was provided by Prof. B.
Trumpower [19].2.3. Measurement of decylubiquinol-cytochrome c reductase activity
Yeast mitochondria were prepared as in [20]. Brieﬂy, yeast grown in
YPGal medium were harvested at mid-log phase. Protoplasts were
obtained by enzymatic digestion of the cell wall using zymolyase in an
osmotic protection buffer. Mitochondria were then prepared by differ-
ential centrifugation following osmotic shock of the protoplasts. Mito-
chondrial samples were aliquoted and stored at−80 °C. Concentration
of bc1 complex in the mitochondrial samples was determined from
dithionite-reduced optical spectra, using ε = 28.5 mM−1 cm−1 at
562 nmminus 575 nm. Decylubiquinol-cytochrome c reductase activities
were determined at room temperature bymeasuring the reduction of cy-
tochrome c (ﬁnal concentration of 20 μM) at 550 nm versus 540 nm over
1-min time-course in 10 mM potassium phosphate pH 7, 0.01% (w/v)
lauryl-maltoside and 1 mM KCN. Mitochondria were added to obtain a
ﬁnal concentration of 5–30 nM bc1 complex. Activity was initiated by
the addition of decylubiquinol, a synthetic analog of ubiquinol (ﬁnal con-
centrations of 2.5–60 μM). Initial ratesweremeasured as a function of the
decylubiquinol concentration. Each measurement was repeated three to
ﬁve times and the values obtained were averaged. kcat were determined
as the cytochrome c reduction rate per bc1 complex. Apparent KM values
were estimated from the plots of cytochrome c reduction rates vs
decylubiquinol concentrations, as the decylubiquinol concentra-
tions required to obtain 50% of the observed maximum rate of cyto-
chrome c reduction. The mid-point inhibition concentrations (IC50)
were determined by inhibitor titration.3. Results
3.1. A Plasmodium-like version of the Qo site in yeast bc1 complex
We have generated a modiﬁed version of yeast bc1 complex with a
Qo site that more closely resembles the parasite Qo site by replacing
ten residues by P. falciparum equivalents (Figs. 1 and 2) [17]. These res-
idues are conserved in all the available Plasmodium sequences.
The resulting Plasmodium-like bc1 complex (named PF-Y279) was
sensitive to atovaquone, a leading antimalarial drug used (in combina-
tion with proguanil) against Plasmodium falciparum.
The most prevalent atovaquone-resistance mutation found in
P. falciparum that associates with malaria treatment failure, namely
Y279S, was introduced in PF-Y279 [17]. The resulting mutant PF-
Y279S was highly resistant to atovaquone (N250-fold compared to PF-
Y279) (Table 1).We alsomonitored the sensitivity of thewt andmutant
enzymes to antimycin and azoxystrobin, two well-known bc1 complex
inhibitors that bind at different target sites: antimycin targets the Qi
site while azoxystrobin binds in the Qo site but in position different to
atovaquone, (i.e. closer to haem bL) [9]. Control and mutants showed
similar sensitivity to these inhibitors.
Fig. 1.Qo site sequences and amino acid substitutions in themutants. Sequence comparison of the Qo site domain between P. falciparum (P.f) and yeast (S.c), wt andmutants PF-Y279, PF2,
PF8 and HS1 is shown. The amino acid substitutions in the Plasmodium-like (PF) and human-like (HS1) mutants are marked in colour. The arrow heads indicate the residues in close
contact with bound atovaquone [10]. C, cd1, ef and F are structural elements within the Qo domain.
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As shown in Fig. 3 and Table 1, the mutated bc1 complexes were
apparently active despite the multiple modiﬁcations of the Qo site.
Cytochrome c reduction activities of PF-Y279 and PF-Y279S (at 20 μM
decylubiquinol) were respectively 43 and 34% of the wt rate. As judged
by the apparent KM for decylubiquinol, the bc1 complex with the PF-like
Qo site had a lower afﬁnity for the substrate than the native enzyme
(7.9 μM for PF-Y279 as compared to 3.1 μM for wt.). It was slightly
lower for PF-Y279S (4.3 μM). Thus the ratio kcat/KM, a second-order rate
constant that gives an estimate of the catalytic efﬁciency, was decreased
from 17 for the wt to 3.9 and 4.2 for PF-Y279 and PF-Y279S, respectively.
As the introduction of multiple mutations in the Qo site could
destabilize the binding of the ISP, shown to be labile in some mu-
tants [21], we monitored the level of that subunit in PF-Y279 and
PF-Y279S. SDS-page followed by Western blot analysis, performed
on mitochondrial samples revealed no decrease in the ISP immuno-
detection signal.
The respiratory growths of PF-Y279 and PF-Y279S mutants were
severely affected. As presented in Fig. 4, PF-Y279 showed a very weak
respiratory growth. PF-Y279S was unable to grow.
We have previously observed that the loss of 60% of the bc1 com-
plex activity had only a moderate effect on respiratory growth [22].
The cut-off value to sustain respiratory growth for our strains and
conditions was between 15 and 20% of wt enzyme activity (unpub-
lished data).
It could thus be expected that mutant bc1 complexes that
showed 43% and 34% of wt activity would support a good respirato-
ry growth.Fig. 2. Structure of theQo site and location of themutations. Cytochrome b is in blue, ISP in orang
The left hand sidepanel shows thewt residues. The right hand side panel shows the Plasmodium
and high lightened in violet. The conserved residue Y279, key for atovaquone binding is in grey.
structure of the yeast bc1 complexwas drawn using the coordinates of PDB ID: 3CX5 and 4PD4. I
molecular modelling images.It seemed therefore that the Plasmodium-likemodiﬁcations of the Qo
site caused a major dysfunction of the enzyme that could not support
growth at the expected level.
3.3. Superoxide over-production
Dysfunction of the Qo site (manifested as electron leak from
semiquinone to oxygen)may result in the overproduction of superoxide
(SO). We thus monitored SO production as the superoxide dismutase
(SOD)-sensitive rate of cytochrome c reduction. The difference between
the reduction rate in the absence and the presence of added SOD gives
the contribution of the cytochrome c reduction by SO to the overall
cytochrome c reductase activity (Fig. 5).
Wild-type bc1 complex did not produce SO, as previously shown [23,
24]. By contrast, 25% of the DQ-cytochrome c reduction activity by PF-
Y279 and PF-Y279S was SOD sensitive. Thus these modiﬁed forms of
bc1 complex produced a signiﬁcant amount of SO.
The overproduction of SO is a clear signiﬁer of Q-cycle dysfunction,
suggestive of increased semiquinone occupancy at Qo, with sub-
sequentially increased probability of oxygen reduction (or other-
wise energetically wasteful electron transfer reactions), with a
signiﬁcant loss of energy [4]. That major dysfunction of the catalytic
mechanism could explain the defective respiratory growth.
In addition, the SO produced by the mutated enzymes might
contribute to the growth defect by damaging ROS-sensitive com-
ponents. We checked whether the respiratory growth competence
of PF-Y279 could be improved by the over-expression of SOD2
(encoding the mitochondrial matrix superoxide dismutase) or
SOD1 (encoding the enzyme localised in the cytoplasm and theewith the Fe–S cluster in yellow and orange, stigmatellin in green and atovaquone in pink.
-like substitutions introduced inmutant PF-Y279. The tenmodiﬁed residues are underlined
Hydrogen atom is inwhite, oxygen in red, nitrogen in dark blue and sulphur in yellow. The
n silicomutationswere introduced using CHIMERA,whichwas also used for generating the
Table 1
bc1 complex activity and sensitivity to inhibitors. Decylubiquinol cytochrome c reduction activities weremonitored as described inMaterials andmethods and reported as the cytochrome
c reduction rates per bc1 complex as a function of decylubiquinol concentration. kcat (at 20 μMdecylubiquinol) and apparent KM values (app.KM) were estimated from the plots presented
in Fig. 3. IC50/bc1, inhibitor concentrations required to reach 50% inhibition were obtained by inhibitor titration and reported on bc1 complex concentration. DQ, decylubiquinol.
Strains Decylubiquinol cytochrome c reductase activity
kcat app. KM kcat/app.KM IC50/bc1
s−1 DQ μM Atovaquone Azoxystrobin Antimycin
Wild-type 53 ± 1.4 3.1 17.0 4 ± 0.6 12 ± 1.2 0.3 ± 0.01
PF-Y279 22.7 ± 0.8 7.9 3.9 2 ± 0.1 12 ± 0.4 0.3 ± 0.01
PF-Y279S 18.2 ± 0.5 4.3 4.2 N500 7 ± 0.9 0.2 ± 0.02
PF-Y279F 54 ± 0.9 6.4 8.9 3 ± 0.1 5 ± 0.3 0.4 ± 0.03
PF-Y279 + H53Y 56.5 ± 3.2 6 9.3 2 ± 0.1 29 ± 2.1 0.8 ± 0.15
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served (not shown).
3.4. Qo site dysfunction caused by the combined Plasmodium-like mutations
The Plasmodium-like Qo site harboured ten amino-acid substitutions
of the yeast Qo site residues: CCVY133–136VLPW, H141Y, L275F, R283K,
MF295–296VL and I299L. We investigated whether the mutated
residue(s) causing the inefﬁcient catalytic activity could be pinpointed.
To that end, we analysed three mutants carrying different combination
of mutations (Fig. 1) [17]. PF2 and PF8 harboured respectively ﬁve
and six of the Plasmodium-like mutations. These are in PF2:
CCVY133–136VLPW, H141Y and L275F and in PF8: L275F R283K,
MF295–296VL and I299L. In HS1, eight residues have been replaced
by the human equivalents: CCVY133–136VLPW, H141F, L275F, F278A and
M295L (Fig. 1).
The respiratory growth and DQ-cytochrome c reductase activity of
thesemutantswere tested. They showedwt or close towt growth and ac-
tivities (data not shown). It seems therefore that the stringent growth de-
fect of PF-Y279 is caused by the combination of the Plasmodium-like
changes.
3.5. Suppressors
In order to getmore information on the dysfunction of the Plasmodi-
um-like bc1 complex, suppressors — respiratory growth competent
cells — were selected from the mutants PF-Y279 and PF-Y279S. For
that end, the mutants were subcloned. Several subclones were grown
in YPD, and then incubated on respiratory medium (YPG). Respiratory
competent clones appeared after a two- or three-week incubation.
Several independent suppressors (each from different subclones)Fig. 3. Decylubiquinol cytochrome c activity. Decylubiquinol cytochrome c reduction
activities were monitored as described in Materials and methods and reported as the
cytochrome c reduction rates per bc1 complex as a function of decylubiquinol concentra-
tion. Each measurement was repeated three to ﬁve times and the values obtained were
averaged. The error-bars represent standard deviations. Wild-type (blue line); mutants
PF-Y279 (orange) and PF-Y279S (grey); suppressors PF-Y279F (yellow) and PF-
Y279 + H53Y (green).were then analysed. The suppressor mutations were identiﬁed as de-
scribed in [25].
From PF-Y279, ten suppressors with a vigorous respiratory growth
were studied. Five harboured a secondary mutation in cytochrome b:
H53Y (obtained twice), H53D (obtained twice) and P174S. In the
other ﬁve suppressors, the compensating mutation was located in the
hinge region of the ISP: A86P, D87G, V88F, L89F and A90T. Interestingly,
residues H53 and P174 are close to the hinge region of the ISP.
Starting from PF-Y279S, suppressors with a very weak respiratory
growth were obtained. The compensating mutations were also located
in the hinge region of the ISP: A86P, D87N, V88A/F/D, L89F and A90V/
D. Interestingly, one suppressor restoring a vigorous respiratory growth
was obtained from PF-Y279S. The mutation replaced Y279S by Y279F.
The resulting strain was named PF-Y279F.
Fig. 6 shows the growth capacity of mutants PF-Y279 and PF-Y279S,
of the suppressor PF-Y279F, of three suppressors issued from PF-Y279
that harbour a compensatory mutation in cytochrome b (H53Y) or in
ISP (A86P and D87G) and of two suppressors issued from PF-Y279S
with a suppressor mutation in ISP (A86P and D87N). On fermentation
medium (YPD), mutants and suppressors grew equally well as the
cells relied on fermentation to proliferate. On respiration medium
(YPG), the impaired growth of PF-Y279 was clearly observed while
PF-Y279S was unable to grow. The combination of PF-Y279S with the
mutation in ISP resulted in a very weak respiratory growth while a
vigorous respiratory growth competence was restored in the other
suppressors.
PF-Y279F and PF-Y279-H53Ywere then analysed inmore details. As
shown in Table 1 and Fig. 3, the additional substitutionY279F orH53Y in
the Plasmodium-like Qo site PF-Y279 resulted in an enzyme with a wt
turnover at 20 μM decylubiquinol but with a higher apparent KM.
Increasing the decylubiquinol concentration above 20 μM result-
ed in severe loss of the activity of PF-Y279-H53Y (Fig. 3). At 40 μM,
its activity was decreased to 18.5 s−1, thus to 32% of the rate at 20 μMFig. 4. Respiratory growth. wt and mutants were pre-grown in YPeth medium, then
inoculated in fresh YPeth medium to obtain an OD600 of 0.1. The cultures were incubated
with vigorous agitation at 28 °C. Growth measured as OD at 600 nm was monitored for
four days. Wild-type (blue line); mutant PF-Y279 (orange) and PF-Y279S (black);
suppressors PF-Y279F (yellow) and PF-Y279 + H53Y (green).
Fig. 5. Superoxide production in wild-type and mutants. PF-Y, PF-Y279; PF-S, PF-Y279S;
PF-F, PF-Y279F and PF-H53Y, PF-Y279+H53Y. Cytochrome c reduction rateswere record-
ed in absence and in presence of SOD and catalase, both at 225 units/mL, using 20 μM
of decylubiquinol. The data are presented as percentage of SOD-sensitive cytochrome
c reduction. The assayswere performed as described inMaterials andmethods, with slight
modiﬁcations made to optimize the SOD and catalase activities: decylubiquinol-
cytochrome c reduction was assayed in potassium phosphate buffer 50 mM pH 7
with 50 μM of cytochrome c and 10 μM of KCN. Each measurement was repeated at
least three times and the data averaged.
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trationwas also observedwithPF-Y279Fbut to a lesser extent, the activity
decreasing from 58 s−1 at 40 μM substrate to 36 s−1 at 60 μM substrate.
This behaviourwas not observedwith PF-Y279 and PF-Y279S. Thewt en-
zyme displayed a small (15%) loss of activity at 40 μMdecylubiquinol. The
sharp loss of activity observedwith PF-Y279-H53Y could be caused by the
weakly chaotropic nature of decyubiquinol that could impair the stability
of the mutant enzyme. We have previously observed a similar behaviour
with a cytochrome b mutant carrying a substitution of residue G167
(G167E), which is located in the cd2 loop of cytochrome b in close contact
with the ISP hinge region [26].
Interestingly, the suppressor mutations signiﬁcantly decreased the
production of SO (Fig. 5). They thus seem to restore a Q-cycle with little
by-pass reactions.
The respiratory growth competence was not fully restored as PF-
Y279F and PF-Y279-H53Y showed a slower growth rate than wt
(Fig. 4). This could be explained, at least in part, by the lower catalytic
efﬁciency estimated by the ratio kcat/apparent KM.Fig. 6. Respiratory growth competence of mutants and suppressors. Serial dilutions
in water of cells pre-grown on glucose plates were spotted on plates containing either
fermentation medium (YPD) or respiration medium (YPG) and incubated for three days
at 28 °C. PF-Y279 (PF-Y); PF-Y279S (PF-S); PF-Y279F (PF-F); suppressors that combined
the Qo site mutations of PF-Y279 with a suppressor mutation in cytochrome b (PF-Y
cytb H53Y) or in ISP (PF-Y ISP A86P and PF-Y ISP D87G); suppressors that combined
the Qo site mutations of PF-Y279S with a suppressor mutation in ISP (PF-S ISP A86P
and PF-S ISP D87N).3.6. Yeast vs Plasmodium falciparum Qo site
The introduction of Plasmodium-like mutations in yeast Qo site
altered the catalytic activity of the bc1 complex, leading to an increase
in the rate of energetically wasteful electron transfer bypass reactions
(as assessed by superoxide production) and by consequence to a
decreased growth competence.
As we found suppressor mutations in and in the vicinity of the ISP
hinge region, we tested whether Plasmodium-like modiﬁcations of the
ISP hinge region could improve the activity of the Plasmodium-like Qo
site in the yeast enzyme and thus restore the respiratory growth compe-
tence of PF-Y279.
The ISP hinge region is formed of 12 residues (residues 81–92 in
yeast sequence), well conserved between yeast and human, but it large-
ly differs in P. falciparumwhere only two residues are conserved (Fig. 7).
That unusual sequence in the parasite, found also in other Apicomplexa,
might be required for the optimal activity of the plasmodial Qo site.
We generated two new versions of the protein by replacing eight
(ISP1) and ten (ISP2) yeast residues by the P. falciparum equivalents
(Fig. 7).
The changes were introduced by site-directed mutagenesis in the
plasmid-borneRIP1gene, encoding yeast ISP [19]. The plasmids carrying
wt or mutated RIP1were then used to transform strains that carry both
a deletion of genomic RIP1 and the wt or the mutated cytochrome b
(PF-Y279). The respiratory growth competence of the mutant strains
was then tested.
As shown in Fig. 7, the combination of the Plasmodium-like version
of the Qo site (PF-Y279) with a modiﬁed Plasmodium-like version of
the ISP hinge region (ISP1) signiﬁcantly improved the respiratory growth
competence. The ISP1 modiﬁcation was also well accommodated in the
bc1 complex with the native Qo site. By contrast, the combination ofFig. 7. Respiratory growth of mutants combining Qo- and ISP-Plasmodium-like modiﬁca-
tions. a) Sequence of the ISP hinge region of human (Hs), yeast (Sc), P. falciparum (Pf),
and yeast mutants with a modiﬁed version of the hinge region (ISP1 and ISP2) where
yeast residues (magenta) have been replaced by the parasite residues (blue). b) Growth
competence of yeast strains that combined a wt Qo site or a PF-Y279 version (PF-Y)
with wt or modiﬁed ISP hinge region (ISP1 and ISP2).
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growth while that same mutation ISP2 slightly improved the growth
of PF-Y279. ISP2 version differs from ISP1 by two additional changes,
M91G and A92G, which seem to have a stringent effect.
We then tested whether the Plasmodium-like modiﬁcations of the
ISP hinge domain could also restore the respiratory growth competence
of themutant PF-Y279S. Themutant strainwas thus transformed by the
plasmids containing the mutated ISP, ISP1 and ISP2 and the growth
competence of the resulting strains was checked. The introduction of
ISP1 resulted in a very weak improvement of the respiratory growth,
very similar to that observed for the ISP-located suppressors selected
from PF-Y279S (as shown in Fig. 6). ISP2 had no effect on the growth
defect of the mutant.
4. Discussion
4.1. Fixing the impaired Qo site
The substitution of ten Plasmodium-like residues in yeast Qo site re-
sulted in a bc1 complex with altered properties, exhibiting decreased
steady-state rates of substrate (decylubiquinol) oxidation and afﬁnity.
Most importantly, the production of SO was signiﬁcantly increased. It
may be hypothesized that, in the mutant strains, the structure of the
Qo site was perturbed and that the interaction of the ISP headgroup
with cytochrome b was altered with respect to wt. Consequently, we
suggest that the observed increase in SO productionwas due to amech-
anistic dysfunction at Qo, resulting in an increased semiquinone occu-
pancy or an increase in the probability of reaction with oxygen by
kinetic or thermodynamic means.
Further modiﬁcations of the site restored nearly full activity:
replacement of Y279 by a phenylalanine or changes in the ISP hinge
region or in the cytochrome b region in close contact with the ISP
hinge region.
A tyrosine is highly conserved at position 279. The residue is likely
to be important for substrate positioning at Qo [27] and is key for
atovaquone binding [10]. The mutation of Y279 leads to resistance to
the antimalarial agent atovaquone in P. falciparum and inmousemalaria
models [12,13,28].
We found previously that in the native yeast Qo site, Y279 could be re-
placed by a phenylalanine without loss of activity [29]. Here we observed
that the substitution of Y279 by a phenylalanine in the Plasmodium-like
Qo site (PF-Y279F) restored the bc1 complex turnover to wt level
and prevented the production of SO.
It has been suggested that Y279 is mechanistically important for the
correct functioning Qo site chemistry, with the sidechain of the residue
acting as a ‘trapdoor’ that gates substrate accessibility to the distal re-
gion of Qo. The positioning of the residue is proposed to be governed
by displacement of the PEWY loop (the ‘PEWY seesaw’) and the docking
of the ISP headgroup at the Qo site [30,31]. This proposed ‘trapdoor’
mechanism is likely to have a role in preventing side-reactions and SO
production byminimising semiquinone occupancy at Qo site, a proposal
supported by the observation of increased ROS production in mutants
equivalent to Y279 in Rhodobacter capsulatus bc1 complex [32]. It may
be postulated that a phenylalanine, having perhaps more degrees of
freedom of movement due to the lack of a potentially hydrogen-
bonding hydroxyl moiety, is a more efﬁcient trapdoor for the Plasmodi-
um-like Qo site. It should be noted that in Plasmodium sp., a tyrosine is
conserved at position 279 (268 in P. falciparum sequence).
If the “trapdoor” is impaired in PF-Y279, re-adjustment of the ISP
movement or docking could compensate the defect, as the respiratory
growth competence of the mutant could be restored by modiﬁcation
of the hinge region of the ISP, namely mutations of ISP residues 86 to
90 andmutations of cytochrome b residues H53 and P174 in the vicinity
of the ISP hinge region. The bc1 complex of the suppressor PF-Y279-
H53Y showed a near wt turnover with little SO production. It is likely
that the other suppressors have the same effect. Thus, the modiﬁcationof the ISP hinge region seems to prevent the production of SO by the al-
tered Qo site.
We suggest that the modiﬁcation of the hinge region results in a
more favourable interaction of the ISP on themutated Qo site facilitating
productive electron transfer and/or restricting accessibility of oxygen to
the semiquinone (or otherwise lessening the probability of the reaction
between semiquinone and oxygen). It is important to note that the pro-
genitor of SO at Qo site, semiquinone, is only formed after oxidation of
Qo-bound quinol by the [2Fe–2S] cluster of the ISP (or re-reduction of
quinone by reduced haem bL). Hence, impaired docking of the ISP at
the Qo site leading to the formation of the initial encounter complex be-
tween cytochrome b, quinol and the ISP, is in itself insufﬁcient to explain
increased rates of SO production in the mutant strains described in this
study. Such impaired dockingwould need to increase the accessibility of
the site to oxygen or increases the degree of semiquinone occupancy
(or, alternatively, reactivity) after the ﬁrst electron transfer reaction at
the Qo site, increasing the likelihood of oxygen reduction. This may
occur if diffusion of the semiquinone intermediate within Qo towards
its productive reaction partner ferrihaem bL is impeded in some way
[8,30], or alternatively by favouring the reduction of product quinone
bound within the proximal region of Qo by ferrihaem bL, regenerating
semiquinone [33–36]. From the investigation of R. capsulatus ISP hinge
(and cytochrome c1)mutants, simple ‘kinetic’models for the instigation
and control of semiquinone chemistry at Qo have been proposed by
Osyczka and colleagues. In these studies, SO generation was demon-
strated to be markedly affected by the degree of ISP occupancy at Qo
and the redox potential of cytochrome c1. As such, it has been proposed
that the nature of the chemistry at Qo (i.e. productive, or bypass) is the
result of the kinetic competition for electrons between redox-active
occupants at this site [37].
4.2. Hinge region suppressor hotspot
The hinge region of the ISP (residues 81–92 in yeast) links the trans-
membrane anchor (residues 51–80) to the extrinsic mobile domain
(residues 93–215). Residues 81–86 are stabilised by hydrogen bonds
and hydrophobic interactions. A helical turn is formed by residues 86–
88 while residues 87–91 are stretched out. At the end of the hinge
region, residue 92 is stabilised by a hydrogen bond with ISP W111
[38]. The ﬂexibility of this hinge region facilitates the movement of the
headgroup, which has been demonstrated to be essential for catalysis
[5,6]. The functional consequences of mutation of the hinge region of
the ISP for electron transfer chemistry at Qo and overall bc1 complex sta-
bility have been extensively investigated in R. capsulatus and yeast.
These studies demonstrated that considerable structural plasticity was
tolerated by the hinge, often without signiﬁcant loss of catalytic func-
tion, but at the expense of complex assembly and stability [6,38,39].
We observed that the severe respiratory defect caused by Qo site
mutations A144F, S152P and G291D [21,25], or by multiple changes
(this work) could, at least partly, be alleviated by mutations in the ISP
hinge region. The compensatory mutations were found in the stretch
from residue 85 to residue 92: T85A/G/I/S, A86L/P/R, D87G, V88A/D/F/
G, L89F, A90D/G/S/T/V, and A92D/G/T. A suppressormutation at residue
93, K93E, immediately downstream of the hinge region was also ob-
served. By contrast, no compensatory mutation was found at residue
M91 or residues 81–84. It thus seems that the stretch T85ADVLA90
(with A92) is a suppressor mutation hotspot. We note that the ISP
hinge mutation A46T has been observed to act as a suppressor for the
cytochrome b T163F mutant in R. capsulatus bc1 complex (residues
equivalent to A90 and T148 respectively in yeast) [40].
Suppressormutations in cytochrome bwere also found, H53D/Y and
P174S. The residues are located in the close vicinity of the hinge region.
Note that H53 is close to the hinge region of the ISP that reacts with the
other monomer.
We previously studied the effect of the cytochrome b mutation
G167E, in the cd2 loop, near P174 and in contact with the ISP hinge
1493Z. Song et al. / Biochimica et Biophysica Acta 1847 (2015) 1487–1494region. The replacement of G167 with glutamate severely impaired the
enzyme activity and stability. We hypothesized that the mutation
affected the structure of the hinge region, resulting in a hinderedmove-
ment and in enzyme instability. This indicated that interfacial protein–
protein interactions between the hinge region of ISP and the extra-
membranous cd2 helix of cytochrome b were important to maintain
the structure of the hinge region, and by consequence the movement
of the headgroup and the integrity of the enzyme [26].
The suppressor mutations that restore the function of PF-Y279,
located in the hinge region or in the cytochrome b cd2 helix in contact
with the hinge region could modify the structure/ propriety of the
hinge region, resulting in an improved interaction between the Qo site
and the ISP.
4.3. Adjustment of the ISP hinge region and the Qo site in the Plasmodium
enzyme
Most interestingly, replacement of the residues of the hinge region
by the Plasmodium equivalents also resulted in a restored respiratory
growth of PF-Y279.
The hinge region of the P. falciparum ISP has a non-canonical se-
quence in the turn at the C-terminus of the transmembrane helix and
the short 310 helical component (residues 81–82 and 86–89 respective-
ly, yeast sequence numbering). These peculiarities are also observed in
other Apicomplexa. The presence of two aromatic residues at positions
81–82 (yeast sequence) in the hinge region of Apicomplexa and replace-
ment of A90 by lysine in the 310 helix might be expected to subtly alter
the structure or mobility of the linker, perhaps extending the 310 helical
component, or favouring the formation of α-helical structure in this
region. These changesmay assist themovement and correct positioning
of the ISP headgroup on the Apicomplexan Qo site for efﬁcient choreog-
raphy of electron transfer at Qo site, while minimising the probability of
unwanted side reactions. It is thus likely that the ISP hinge region andQo
site of cytochrome b have co-evolved to this end.
Recent data suggest that mitochondrial metabolic plasticity is essen-
tial for malaria parasite development across its complex life cycle with
different needswhether in the vertebrate host or in themosquito vector
[41]. During the asexual intraerythrocytic replicative stage, the ATP de-
mands of the parasite are largely met by glycolysis, and the role of the
mitochondrial respiratory chain for energy generation seems to be
minor [41]. However, bc1 complex activity remains crucial for the estab-
lishment of the transmembrane proton motive force (which aside from
ATP generation is necessary for protein import into the mitochondrion)
and for the reoxidation of ubiquinol and the activity of the ubiquinone-
dependent dihydroorotate dehydrogenase, and therefore the biosyn-
thesis of pyrimidine [42]. In contrast, the parasite heavily relies on the
respiratory chain for energy production during sexual stages and devel-
opment within the mosquito. Therefore, an efﬁcient bc1 complex cata-
lytic activity would be required, with minimal Qo bypass chemistry
and production of damaging SO.
4.4. Atovaquone-resistance mutation Y279S and defective respiratory
function
By contrast to PF-Y279, the Plasmodium-like modiﬁcation of the ISP
hinge region did not restore— or very weakly— the respiratory growth
competence of PF-Y279S, which carried the atovaquone resistance mu-
tation Y279S reported in P. falciparum and causing treatment failures.
The same behaviour was observed with suppressor mutations in the
ISP hinge region as only a very poor compensation of the respiratory
growth defect was observed (as shown in Fig. 6). This was not un-
expected as it was found that substitution of Y279 by a serine, in the
yeast native form of the Qo site, results in a signiﬁcant decrease of the
complex activity [43]. We observed that a tyrosine or a phenylalanine
were required at that position to obtain a fully functional enzyme [29].The severe respiratory defect caused by Y279S— in the Plasmodium-
like yeast bc1 complex — is in agreement with the data obtained with
P. falciparum. In the parasite also, the acquisition of atovaquone resis-
tance is associated with loss of bc1 complex activity and decreased
ﬁtness [44].
5. Conclusions
A Plasmodium-like Qo site is not well accommodated in the yeast bc1
complex. However, the “inter-species incompatibility” could be over-
come by introducing a Plasmodium-like hinge region in the ISP, which
is likely to restore a correct interaction between the two catalytic part-
ners. The novel chimeric Plasmodium-like bc1 complex seems a reliable
model of the parasite enzyme and could be a useful tool to identify
new drugs with potential anti-Apicomplexa activity targeting the bc1
complex Qo site.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbabio.2015.08.005.
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